GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Morphic Holding Inc.
MultiPlan is a company that helps insurance companies reduce their healthcare costs. Its stock price is a story of struggle against legislative changes and customer pressure.
Share prices of companies in the market segment - Pharma git
Morphic Holding is a biopharmaceutical company developing oral integrin-based therapies for the treatment of autoimmune and inflammatory diseases. We have classified it in the Pharma: Gastrointestinal tract. The chart below shows how investors evaluate innovative approaches in biotechnology.
Broad Market Index - GURU.Markets
Morphic is a biotech company developing oral integrin-based therapies for the treatment of autoimmune and inflammatory diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Morphic shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
MORF - Daily change in the company's share price Morphic Holding Inc.
For Morphic Holding, Inc., a biopharmaceutical company, daily price change is a measure of its extreme volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma git
Morphic Holding is a biopharmaceutical company developing oral integrin-based drugs. This is a cutting-edge area of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with MORF's clinical trials.
Daily change in the price of a broad market stock, index - GURU.Markets
Morphic is a biotech company specializing in the treatment of gastrointestinal diseases. Its shares are driven by news of clinical trials. This high, event-driven volatility feeds into the overall flow of market movements, shaping its daily pattern.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Morphic Holding Inc.
Morphic Holding, Inc.'s year-over-year performance is a story of its integrin-based oral drug development. Its 12-month market cap is entirely dependent on clinical trial data. Its partnership with AbbVie is a key validation of its platform's potential for creating a new class of drugs.
Annual dynamics of market capitalization of the market segment - Pharma git
Morphic, a late-stage biotech company, develops drugs for the treatment of gastrointestinal diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Morphic, a biopharmaceutical company developing oral drugs for autoimmune diseases, is a breakthrough story. Its year-over-year market capitalization is driven by progress in clinical trials and the potential of its platform to create "pills" instead of injections.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Morphic Holding Inc.
Morphic is a clinical-stage biopharmaceutical company focused on gastrointestinal diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its leading programs are binary outcomes for its stock.
Monthly dynamics of market capitalization of the market segment - Pharma git
This chart reflects the dynamics of the biotech sector. For Morphic, a clinical-stage company, it's the backdrop. Its volatile movements demonstrate how investor expectations surrounding the results of its drug trials are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Morphic Holding is a biotech company developing small-molecule drugs for the treatment of autoimmune and inflammatory diseases. Its value is determined by progress in clinical trials. The overall market chart provides only background information, while Morphic's performance is driven by development news, which is typical for the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Morphic Holding Inc.
The weekly performance of Morphic, a biotech company developing oral medications for autoimmune diseases, reflects progress in this field. Its stock price is responding to clinical trial data that could offer a more convenient alternative to injectable medications.
Weekly dynamics of market capitalization of the market segment - Pharma git
Morphic Holding develops oral integrin-based drugs. This is a new class of drugs with significant potential. This chart compares its volatile, news-driven performance with the pharmaceutical sector and helps us understand the level of investor confidence in its innovative scientific platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Morphic is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Morphic is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
MORF - Market capitalization of the company Morphic Holding Inc.
Morphic's market capitalization tells the story of a biotech company developing oral drugs for the treatment of autoimmune diseases. Its volatile price action is a direct response to clinical trial data. Its price action reflects investors' assessment of the potential of its scientific platform and the chances of creating a convenient alternative to injections.
MORF - Share of the company's market capitalization Morphic Holding Inc. within the market segment - Pharma git
Morphic Holding is a biotech company developing a new generation of oral drugs. Its sector weight reflects investor expectations for the success of its clinical trials. The chart below shows how development news affects its share of the overall industry market capitalization.
Market capitalization of the market segment - Pharma git
Morphic is a biotech company developing oral medications for the treatment of autoimmune diseases. The chart below shows the overall market capitalization of this research-intensive sector. Its dynamics reflect Morphic's hopes for the development of convenient tablet-based medications instead of injections.
Market capitalization of all companies included in a broad market index - GURU.Markets
Morphic Holding is a biotech company developing oral medications for the treatment of autoimmune diseases. Its market capitalization is a bet on the possibility of creating convenient pills instead of injections. Its performance on the overall chart reflects how the market values innovations that can dramatically improve patients' quality of life.
Book value capitalization of the company, segment and market as a whole
MORF - Book value capitalization of the company Morphic Holding Inc.
Morphic Holding's book value is its capital invested in clinical trials of oral medications (in tablet form) for the treatment of autoimmune diseases. This provides a tangible, scientific foundation for creating a more convenient alternative to injections. How has this biotech asset changed? The chart below shows its dynamics.
MORF - Share of the company's book capitalization Morphic Holding Inc. within the market segment - Pharma git
Morphic Holding is developing a new class of oral drugs, which requires advanced chemical and biological laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its innovation platform.
Market segment balance sheet capitalization - Pharma git
Morphic, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as the primary capital here is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Morphic's balance sheet is its scientific platform for developing small-molecule integrin-targeted drugs for the treatment of autoimmune diseases. The company's assets are its intellectual capital and research data. The chart below shows how this science-intensive R&D asset compares to big pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Morphic Holding Inc.
The balance sheet of biotech Morphic Holding reflects research and development expenses. Its market value, however, reflects investors' pure expectations for the success of its drug discovery platform. The chart shows the high level of hope for a scientific breakthrough capable of transforming the pharmaceutical market.
Market to book capitalization ratio in a market segment - Pharma git
Morphic Holding is a biotech company developing a new class of oral integrin-based drugs (tablets). Its high market valuation, as shown in the chart, reflects the enormous potential of its scientific platform, which could replace injectable treatments for many diseases.
Market to book capitalization ratio for the market as a whole
Biopharmaceutical company Morphic Holding, Inc. is at the forefront of science, where value is created by intellectual property, not manufacturing capacity. The market values the potential of its developments, resulting in a high valuation. This chart shows how much the premium for scientific innovation exceeds the market average.
Debts of the company, segment and market as a whole
MORF - Company debts Morphic Holding Inc.
Morphic Holding, a clinical-stage biotech developing oral integran-based drugs, is using capital to fund its expensive research. This chart shows how the company is raising significant funds to validate its innovative scientific platform, which could change the treatment of many diseases.
Market segment debts - Pharma git
Morphic Holding is a clinical-stage biotech company developing oral therapies for autoimmune diseases. Funding at this stage relies almost entirely on equity. This chart illustrates a typical industry-standard financial model with minimal or no leverage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Morphic Holding Inc.
Morphic Holding is a biotech company developing a new class of oral drugs. Its success depends on the results of clinical trials. This chart shows the extent to which the company finances its expensive research with debt. It is a direct measure of its financial risk on the long road to potential development of a new drug.
Market segment debt to market segment book capitalization - Pharma git
Morphic Holding is a biotech company developing oral medications (tablets) for the treatment of autoimmune and inflammatory diseases. The chart shows how aggressively the biotech sector uses debt to fund expensive clinical trials, providing context for assessing Morphic's financial strategy and risks.
Debt to book value of all companies in the market
Morphic Holding, Inc., a clinical-stage biopharmaceutical company, requires significant and ongoing investment to develop its innovative drugs. This chart, showing the market's overall debt load, allows one to assess how typical its financial strategy is for biotech, where the path from lab to pharmacy is long and capital-intensive.
P/E of the company, segment and market as a whole
P/E - Morphic Holding Inc.
Morphic Holding is a biopharmaceutical company developing a new class of oral integrin-based drugs for the treatment of autoimmune and inflammatory diseases. This chart shows how investors value its scientific platform. The valuation depends on success in clinical trials and the potential to create convenient tablet-based alternatives to injectable drugs.
P/E of the market segment - Pharma git
This chart for biotech companies serves as a benchmark for Morphic Holding. It reflects generally high valuations based on hopes for a breakthrough. Comparison with this chart helps understand whether Morphic's innovative platform for developing oral medications (in tablet form) for the treatment of autoimmune diseases is considered more promising than its competitors.
P/E of the market as a whole
Morphic is a biotech company developing a new class of oral drugs for the treatment of autoimmune diseases. Its valuation is a pure bet on the success of its scientific platform. It has no connection to the general economic cycles depicted by this chart. Morphic's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Morphic Holding Inc.
For Morphic Holding, Inc., a biopharmaceutical company developing oral integrin-based therapies, this chart illustrates market expectations for its clinical programs. It reflects investor confidence in the potential of this new technology for treating autoimmune and other serious diseases.
%20P%2FE%20Morphic%20Holding%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Morphic-Holding-Inc.&v=1772513608063 "Chart of the company's future (projected) P/E Morphic Holding Inc.")
Future (projected) P/E of the market segment - Pharma git
Morphic Holding is a biopharmaceutical company developing oral integrin inhibitor-based drugs for the treatment of autoimmune and fibrotic diseases, such as ulcerative colitis. The chart shows industry forecasts, allowing for a comparison of how the market views Morphic's innovative approach and the potential of its developments to become an alternative to injections.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-git&v=1772513608108 "Future (projected) P/E graph of the market segment - Pharma git")
Future (projected) P/E of the market as a whole
Morphic Holding, Inc. is a biopharmaceutical company developing a new class of oral medications (tablets) to treat diseases that previously required injections. This is a breakthrough technology. This chart shows how much the market is willing to pay for scientific platforms that have the potential to change the standard of care.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513608120 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Morphic Holding Inc.
Morphic Holding is a biopharmaceutical company developing oral integrin-based drugs for the treatment of autoimmune and fibrotic diseases. While in the clinical stage, it is losing money. This chart illustrates the financial implications of developing a new class of drugs that could replace injectables.
Profit of companies in the market segment - Pharma git
Morphic Holding is a biopharmaceutical company developing oral integrin-based drugs for the treatment of autoimmune and fibrotic diseases. This chart, which shows the pharmaceutical sector's profitability, illustrates the investment climate. Their goal is to create convenient tablet formulations of drugs instead of injections, and success depends on data from their clinical trials.
Overall market profit
Morphic Holding is a biopharmaceutical company developing a new class of oral integrin-based drugs. It is a cutting-edge scientific platform with broad potential. Funding for such innovative companies depends on overall market conditions. Growing corporate profits, as shown in this chart, increases investor appetite for risky but promising biotechnologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Morphic Holding Inc.
Morphic Holding develops oral integrin-based drugs for the treatment of autoimmune and inflammatory diseases currently treated with injections. This graph represents the quintessence of analysts' expectations for clinical trial success, betting on a breakthrough in the treatment of chronic diseases.
%20profit%20of%20the%20company%20Morphic%20Holding%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Morphic-Holding-Inc.&v=1772513608202 "Graph of future (projected) profit of the company Morphic Holding Inc.")
Future (predicted) profit of companies in the market segment - Pharma git
Morphic Holding is a biopharmaceutical company developing a new generation of oral integrin-based drugs for the treatment of autoimmune and inflammatory diseases. Its future depends on the success of clinical trials. This biotech chart reflects the overall investor confidence in the potential of innovative approaches to treating chronic diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-git&v=1772513608249 "Graph of future (predicted) profits of companies in a market segment - Pharma git")
Future (predicted) profit of the market as a whole
Morphic Holding is a biotech company developing oral medications. Its success depends on scientific breakthroughs. However, the overall economic climate reflected in this forecast impacts the availability of capital to finance the lengthy and costly clinical trials required to bring drugs to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513608303 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Morphic Holding Inc.
Morphic Holding is a biopharmaceutical company developing oral medications for the treatment of autoimmune diseases. For a clinical-stage company, this chart is key. It shows how investors evaluate the potential future sales of its innovative drugs, betting on a breakthrough in the treatment of chronic inflammation.
P/S market segment - Pharma git
Morphic Holding is developing a new class of oral integrin-targeted drugs for the treatment of autoimmune and inflammatory diseases. The company's valuation is based on the potential of its scientific platform. This chart reflects the average valuation in the biotech industry, allowing investors to understand how expectations for Morphic's innovative technology align with industry trends.
P/S of the market as a whole
Morphic Holding is a biopharmaceutical company developing a new class of oral integran-based drugs for the treatment of autoimmune and inflammatory diseases. This chart, which reflects revenue estimates for real businesses, highlights that Morphic's valuation is a bet on its innovative scientific platform, which can create convenient tablet-based analogues of injectable drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Morphic Holding Inc.
Morphic Holding is a biotech company developing oral integrin-based therapies for the treatment of autoimmune and fibrotic diseases. Its goal is to transform injectable therapies into convenient tablets. This graph reflects investor expectations regarding the success of its clinical programs and the commercial potential of its innovative approaches.
%20P%2FS%20Morphic%20Holding%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Morphic-Holding-Inc.&v=1772513608524 "The graph of the company's future (projected) P/S Morphic Holding Inc.")
Future (projected) P/S of the market segment - Pharma git
Morphic Holding, Inc. is a biopharmaceutical company developing a new generation of oral integrin-targeted therapies for the treatment of autoimmune and fibrotic diseases. This chart reflects average revenue expectations for the biotech sector and provides insight into the market's appreciation of Morphic's innovative drug discovery platform.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20git&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-git&v=1772513608592 "Future (projected) P/S market segment graph - Pharma git")
Future (projected) P/S of the market as a whole
Morphic Holding is a biotech company developing a new generation of oral integrin-based drugs for the treatment of autoimmune and inflammatory diseases. The chart below shows how the market generally views its revenue growth prospects. Morphic's success could offer patients more convenient and effective therapy, fueling investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513608665 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Morphic Holding Inc.
This chart illustrates the revenue of Morphic Holding, a clinical-stage biopharmaceutical company developing oral medications for autoimmune diseases. Its revenue is generated not from sales but from payments under strategic partnerships with major pharmaceutical companies, reflecting progress in research and development.
Sales of companies in the market segment - Pharma git
Morphic Holding is a biopharmaceutical company developing oral medications for the treatment of autoimmune and fibrotic diseases. This chart shows the potential market for these therapeutic areas. Morphic's success in creating convenient tablet formulations that replace injections could radically change treatment standards and capture significant market share.
Overall market sales
Morphic Holding is a biopharmaceutical company developing oral medications for the treatment of chronic diseases. Its market capitalization depends on progress in clinical trials. The overall economic situation, reflected in this chart, influences the availability of capital for funding long-term biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Morphic Holding Inc.
Morphic Holding is a biotech company developing oral medications for the treatment of autoimmune diseases. Future revenue depends on the success of clinical trials and the potential of its drugs. The chart reflects analyst expectations for the commercialization of this new class of therapy.
%20sales%20of%20the%20company%20Morphic%20Holding%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Morphic-Holding-Inc.&v=1772513608939 "Schedule of future (projected) sales of the company Morphic Holding Inc.")
Future (projected) sales of companies in the market segment - Pharma git
Morphic Holding is a biopharmaceutical company developing a new generation of oral drugs targeting a class of proteins called integrins for the treatment of autoimmune diseases. This chart shows the forecast for the entire pharmaceutical market, where the development of convenient tablet forms for the treatment of chronic diseases is the Holy Grail.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-git&v=1772513609026 "Schedule of future (projected) sales of companies in the market segment - Pharma git")
Future (projected) sales of the market as a whole
Morphic Holding is a clinical-stage biotechnology company developing oral integrative therapies for the treatment of autoimmune and inflammatory diseases. Its valuation is dependent on the success of clinical trials. This graph, reflecting overall market sentiment, impacts the availability of capital for funding long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513609038 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Morphic Holding Inc.
Morphic Holding is a biotech company developing oral medications for diseases that traditionally require injections. Being in the clinical trials stage, it incurs significant R&D expenses. This chart shows its net losses—investments in science that could make treatment more convenient and accessible for millions of patients.
Market segment marginality - Pharma git
Morphic Holding is a biopharmaceutical company developing a new generation of oral drugs for the treatment of autoimmune and fibrotic diseases. At the clinical stage, profitability is a long-term goal. This chart reflects research investments. Investors analyze it to assess the potential of their platform for creating more convenient treatments.
Market marginality as a whole
Morphic Holding is a biotech company developing oral drugs targeting integrins, a class of proteins involved in the development of many diseases. Their approach could replace injectable therapies. This overall profitability curve is unimportant to them. Their future depends solely on the success of their scientific platform and the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Morphic Holding Inc.
Morphic Holding is a biotechnology company developing oral medications for the treatment of autoimmune diseases. Its team consists of highly qualified scientists. The growth on this chart is a clear indicator of the progress of its clinical programs and the expansion of its research platform.
Share of the company's employees Morphic Holding Inc. within the market segment - Pharma git
Morphic Holding is a biopharmaceutical company developing a new class of oral drugs for the treatment of autoimmune and fibrotic diseases. This chart shows its share of the total number of researchers in this niche area. The growth in this figure indicates progress in clinical trials and the expansion of the scientific team working on breakthrough drugs.
Number of employees in the market segment - Pharma git
Morphic Holding, Inc. is a biopharmaceutical company developing a new generation of orally administered small-molecule therapeutics targeting integrins. This chart shows the dynamics of employment in this cutting-edge area of drug development. The growing number of scientists here signals progress in developing drugs for autoimmune and fibrotic diseases that can be taken as tablets.
Number of employees in the market as a whole
Morphic Holding is a biotech company developing oral medications. Its development requires significant investment in clinical research. Overall economic stability, illustrated by this chart, influences the availability of venture capital and the willingness of large pharmaceutical companies to enter into partnerships, which is critical for Morphic.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Morphic Holding Inc. (MORF)
Morphic Holding is a biotech company developing next-generation drugs (integrin inhibitors). Like many clinical-stage companies, its staff consists of highly qualified scientists and it has no revenue. This chart demonstrates that its market value is completely disconnected from current productivity and reflects solely the valuation of its intellectual property and the potential of its scientific platform.
%20of%20the%20company%20Morphic%20Holding%20Inc.%20(MORF)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Morphic-Holding-Inc.-MORF&v=1772513609142 "Chart of market capitalization per employee (in thousands of dollars) of the company Morphic Holding Inc. (MORF)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma git
Morphic Holding is a biotech company developing oral medications for the treatment of autoimmune and inflammatory diseases. Its value is determined by the potential of its scientific platform and clinical development. This chart demonstrates the high valuation of its intellectual property based on its small team of scientists.
%20by%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-git&v=1772513609159 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma git")
Market capitalization per employee (in thousands of dollars) for the overall market
Morphic Holding is a biopharmaceutical company developing a new class of oral drugs (integrins) for the treatment of chronic diseases. The chart illustrates the valuation of the research platform. It shows how the market perceives the potential of their technology, where the contribution of a small team of scientists can lead to the creation of breakthrough drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513609174 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Morphic Holding Inc. (MORF)
Morphic Holding is a clinical-stage biotech company developing a new class of drugs—oral (tablet-formed) integrin inhibitors. This is R&D. This chart shows the company's capital burn: the amount of capital the company spends on each scientist trying to turn a complex scientific platform into a commercially successful drug.
%20Chart%20Morphic%20Holding%20Inc.%20(MORF)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Morphic-Holding-Inc.-MORF&v=1772513609190 "Company Profit Per Employee (in thousands of dollars) Chart Morphic Holding Inc. (MORF)")
Profit per employee (in thousands of dollars) in the market segment - Pharma git
Morphic Holding is a clinical-stage biotech company developing oral medications for the treatment of autoimmune diseases. Like other R&D companies, this metric is negative. It reflects targeted investments in research and clinical trials rather than operating losses.
%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-git&v=1772513609212 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma git")
Profit per employee (in thousands of dollars) for the market as a whole
Morphic Holding is a clinical-stage biotech company specializing in the treatment of autoimmune gastrointestinal diseases. It's an R&D company and has no profit. This chart shows the company's capital burn rate: the operating loss calculated per team of scientists developing a new drug through expensive clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513609226 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Morphic Holding Inc. (MORF)
Morphic Holding is a biopharmaceutical company developing oral drugs for the treatment of autoimmune diseases. This chart reflects the progress of monetizing its scientific platform. The revenue growth at this stage is likely due to upfront payments from major partners who believe in the potential of its developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Morphic-Holding-Inc.-MORF&v=1772513609239 "Sales chart per company employee Morphic Holding Inc. (MORF)")
Sales per employee in the market segment - Pharma git
Morphic Holding is a biotech company developing a new generation of oral medications (tablets) for the treatment of autoimmune diseases. While in the clinical stage, their revenue comes from partner fees. This chart shows how productive their R&D team is in attracting capital from large pharmaceutical companies per scientist.
Sales per employee for the market as a whole
Morphic Holding is a clinical-stage biotech company developing a new generation of oral integrin-based drugs for the treatment of autoimmune diseases. The company has no commercial revenue yet. This chart illustrates a typical R&D situation: an entire staff of highly qualified scientists is working on developing future drugs, consuming investor capital.
Short shares by company, segment and market as a whole
Shares shorted by company Morphic Holding Inc. (MORF)
Morphic Holding is a biotech company developing oral medications (pills) to treat conditions that previously required injections. This chart shows bearish bets. Investors are betting that its complex drug candidates will fail to prove their efficacy or safety in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Morphic-Holding-Inc.-MORF&v=1772513609303 "Short Shares Chart for the Company Morphic Holding Inc. (MORF)")
Shares shorted by market segment - Pharma git
Morphic Holding is a biotech company developing a new generation of oral medications (tablets) for the treatment of diseases that previously required injections, with a focus on the gastrointestinal tract. This chart shows the aggregate short positions across the entire biotech sector focused on integrated therapies. It measures the market's skepticism about the success of this complex scientific platform, anticipating failure in clinical trials.
Shares shorted by the overall market
Morphic (MORF) is a clinical-stage biotech. Its value reflects the hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Morphic Holding Inc. (MORF)
This chart for Morphic is a binary biotech bet. The company is developing oral medications (pills) for autoimmune diseases, attempting to replace injections. "Overheating" (above 70) occurs on positive trial data or news of a partnership with Big Pharma (like J&J). A clinical failure would immediately plunge the stock.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Morphic-Holding-Inc.-MORF&v=1772513609413 "RSI 14 indicator chart for the company's stock Morphic Holding Inc. (MORF)")
RSI 14 Market Segment - Pharma git
Morphic (MORF) is a biotech company developing "pills" (oral medications) for the treatment of autoimmune diseases, where injections currently dominate. This chart tracks overall sentiment in the Pharma/GI sector. It helps investors understand whether MORF's performance reflects its science or whether the entire biotech sector is overheated or oversold.
RSI 14 for the overall market
For Morphic, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MORF (Morphic Holding Inc.)
Morphic (MORF) is a biotech developing oral integrin inhibitors for the treatment of autoimmune and fibrotic diseases (e.g., ulcerative colitis). This chart shows the speculative average 12-month price target from analysts based on their belief in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MORF-Morphic-Holding-Inc.&v=1772513609475 "A chart showing analyst consensus forecasts for the expected stock price. MORF (Morphic Holding Inc.)")
The difference between the consensus estimate and the actual stock price MORF (Morphic Holding Inc.)
Morphic (MORF) is a biotech developing oral integrin inhibitors for the treatment of autoimmune diseases (GI). This chart shows the upside and downside potential of the stock that analysts see. It measures the gap between the price and the forecast, reflecting their confidence in this R&D platform and the chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MORF-Morphic-Holding-Inc.&v=1772513609501 "A chart showing the difference between the consensus forecast and the actual stock price. MORF (Morphic Holding Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma git
Morphic (MORF) is a biotech company focused on transforming complex biologic (injectable) drugs into simple oral (pill) options for treating autoimmune diseases such as ulcerative colitis. This chart reflects the collective opinion of the *entire* pharmaceutical (GI/autoimmune) sector. It shows whether experts believe in the R&D success of oral inhibitors.
Analysts' consensus forecast for the overall market share price
Morphic is a biotech company specializing in the development of oral (tablet-based) drugs for the treatment of autoimmune and inflammatory diseases. This chart shows the overall market "risk appetite." For MORF, a high-risk clinical-stage company, overall market optimism (a rising chart) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Morphic Holding Inc.
Morphic is a biotech R&D company focused on immunology. Their signature R&D platform (integrin inhibitors) enables the creation of oral (tablet-based) drugs for the treatment of gastrointestinal diseases (Crohn's disease). They're betting on replacing injections (like Entyvio). This chart is a pure R&D barometer of faith/fear. It reflects the market's assessment of their (very risky) pipeline.
AKIMA Market Segment Index - Pharma git
Morphic (MORF) is a biotech focused on integrins. They are developing oral medications for the treatment of gastrointestinal diseases (Crohn's disease) and fibrosis. They are a gastrointestinal pharma company. This chart compares their composite index to the sector, showing how their integrin platform compares to others.
The AKIM Index for the overall market
Morphic Holding is a biopharmaceutical company developing oral integrin inhibitors for the treatment of IBD. It is being acquired by Eli Lilly. This chart, which reflects the market average, provides a macro backdrop. It helps assess how MORF, a successful scientific company, fared against the backdrop of overall economic trends before the acquisition.
